LON:SLN Silence Therapeutics (SLN) Share Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free SLN Stock Alerts GBX 535 -5.00 (-0.93%) (As of 11/29/2021) Add Compare Share Share Today's Range 512▼ 54650-Day Range 535▼ 53552-Week Range 411▼ 680Volume913,528 shsAverage Volume80,100 shsMarket Capitalization£480.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Silence Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Silence Therapeutics Stock (LON:SLN)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Read More SLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLN Stock News HeadlinesApril 22, 2024 | markets.businessinsider.comBeyond The Numbers: 7 Analysts Discuss Silence Therapeutics StockApril 20, 2024 | americanbankingnews.comSilence Therapeutics (LON:SLN) Share Price Passes Below 200 Day Moving Average of $535.00April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 13, 2024 | nasdaq.comSilence Therapeutics Plc American Depository Share (SLN)March 28, 2024 | msn.com‘Quiet on Set’ to Launch Fifth Episode ‘Breaking the Silence’ With New Drake Bell Interview and MoreMarch 13, 2024 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 13, 2024 | msn.comSilence Therapeutics gains on mid-stage win for lead assetFebruary 23, 2024 | msn.comSilence Therapeutics Jumps on Clinical TrialsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. February 7, 2024 | finance.yahoo.comBroker Revenue Forecasts For Silence Therapeutics plc (NASDAQ:SLN) Are Surging HigherJanuary 31, 2024 | realmoney.thestreet.comIs Silence Golden for This Small-Cap Biotech Stock?January 31, 2024 | finance.yahoo.comSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 11, 2024 | msn.comAll You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong BuyJanuary 5, 2024 | finance.yahoo.comSilence Therapeutics PLC Sponsored ADR (SLN) Is a Great Choice for 'Trend' Investors, Here's WhyDecember 24, 2023 | finance.yahoo.comThis Silence Therapeutics Insider Increased Their Holding In The Last YearDecember 15, 2023 | finance.yahoo.comHere's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep goingDecember 6, 2023 | finance.yahoo.comDoes Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?November 21, 2023 | morningstar.comSilence Therapeutics PLC ADR SLNNovember 16, 2023 | markets.businessinsider.comSilence Therapeutics: Bullish Outlook on SLN360 and Future Potential Despite Thalassemia Program DiscontinuationNovember 1, 2023 | markets.businessinsider.comIs This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease CandidateNovember 1, 2023 | marketwatch.comSilence Therapeutics ADRs Rise 22% After Positive Trial ResultsOctober 27, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday TradingOctober 14, 2023 | msn.comAT&T Unveils “Sound of Silence” Ad to Tout 5G Football Helmet PartnershipSeptember 26, 2023 | finance.yahoo.comSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceAugust 17, 2023 | markets.businessinsider.comWhere Silence Therapeutics Stands With AnalystsJune 25, 2023 | fool.comSilence Therapeutics Plc (NASDAQ: SLN)May 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Silence TherapeuticsSee More Headlines Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/14/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SLN CUSIPN/A CIKN/A Webwww.silence-therapeutics.com Phone+44-20-34576900FaxN/AEmployees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.80 Current Ratio4.52 Quick Ratio4.36 Sales & Book Value Annual Sales£11.35 million Price / Sales42.34 Cash FlowGBX 84.41 per share Price / Cash Flow6.34 Book ValueGBX 18.20 per share Price / Book29.40Miscellaneous Outstanding Shares89,785,000Free FloatN/AMarket Cap£480.35 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Mark Andrew Rothera (Age 58)Pres, CEO & Exec. Director Comp: $521.23kDr. Giles V. Campion M.D. (Age 67)Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director Comp: $436.2kMr. Craig A. Tooman M.B.A. (Age 55)MBA, Chief Financial Officer Ms. Gem Gokmen HopkinsHead of IR & Corp. CommunicationsDr. Barbara A. Ruskin (Age 61)Sr. VP, Gen. Counsel & Chief Patent Officer Ms. Linnea ElringtonVP & Head of HRDr. John StraffordVP & Head of Bus. Devel.Mr. Jørgen WittendorffSr. VP & Head of ManufacturingDr. Marie Wikstrom Lindholm Ph.D.Sr. VP & Head of Molecular DesignMore ExecutivesKey CompetitorsPureTech HealthLON:PRTCHorizon Discovery Group plc (HZD.L)LON:HZDErgomedLON:ERGOBioventixLON:BVXPVerona Pharma plc (VRP.L)LON:VRPView All Competitors SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed in 2024? Silence Therapeutics' stock was trading at GBX 535 on January 1st, 2024. Since then, SLN stock has increased by 0.0% and is now trading at GBX 535. View the best growth stocks for 2024 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (LON:SLN) issued its quarterly earnings data on Monday, September, 14th. The company reported ($13.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($21.70) by $8.00. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA). How do I buy shares of Silence Therapeutics? Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SLN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
